Immunome IMNM Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunome's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunome's operating lease liabilities?
- Immunome (IMNM) reported operating lease liabilities of $3.69M in Q1 2026.
- How has Immunome's operating lease liabilities changed year-over-year?
- Immunome's operating lease liabilities decreased by 22.6% year-over-year, from $4.77M to $3.69M.
- What is the long-term trend for Immunome's operating lease liabilities?
- Over 2 years (2023 to 2025), Immunome's operating lease liabilities has grown at a 69.6% compound annual growth rate (CAGR), from $1.34M to $3.86M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.